A recent study has made significant strides in uncovering how the oral microbiome, particularly the bacterium Fusobacterium nucleatum, plays a crucial role in the progression of oral squamous cell carcinoma (OSCC).

NCCN—an alliance of leading cancer centers—publishes a new resource to inform people about the latest recommendations around hereditary and familial cancer risk.

EPFL scientists have used deep learning to design new proteins that bind to complexes involving other small molecules like hormones or drugs, opening up a world of possibilities in the computational design of molecular interactions for biomedicine.

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

The FDA ban on Red Dye 3, cancer survivorship and what it  means to live with cancer, global trends in lung cancer deaths, researching gynecologic cancer disparities in women of Arican ancestry and more are included in Sylvester Cancer's January tip sheet.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. 

A new publication from Opto-Electronic Advances; DOI  10.29026/oea.2024.240105, discusses a high-resolution tumor marker detection based on microwave photonics demodulated dual wavelength fiber laser sensing system for the early screening of cancer.

 

Three researchers from Pennington Biomedical Research Center served on the Lancet Commission on Clinical Obesity, a global group that generated a new approach to diagnosing clinical obesity. The diagnosis is based on evaluations in addition to body mass index, or BMI, such as measures of excess body fat and objective signs and symptoms of ill health at the individual level. The Lancet Commission on Clinical Obesity was made up of 56 individuals from around the world, including Dr. John Kirwan, Executive Director and George A. Bray, Jr. Endowed Super Chair in Nutrition; Dr. Eric Ravussin, LSU Boyd Professor and Douglas L. Gordon Chair in Diabetes and Metabolism; and Dr. Philip Schauer, Director of the Metamor Institute and United Companies Life Insurance Co./Mary Kay and Terrell Brown Chair.